Solana still dazzles with scalability and tiny fees, while Pepeto is the breakout meme coin with heavy backing, fast presale […] The post Solana And Pepeto Should Be On Your Radar Today,As SUI Struggles appeared first on Coindoo.Solana still dazzles with scalability and tiny fees, while Pepeto is the breakout meme coin with heavy backing, fast presale […] The post Solana And Pepeto Should Be On Your Radar Today,As SUI Struggles appeared first on Coindoo.

Solana And Pepeto Should Be On Your Radar Today,As SUI Struggles

2025/10/06 23:44
3 min read

Solana still dazzles with scalability and tiny fees, while Pepeto is the breakout meme coin with heavy backing, fast presale traction, and rich staking rewards. With SUI drifting, smart diversification points to these two high-potential names right now.

Solana (SOL) Potential For Long Term Growth

Analysts still place Solana near the top of any buy list. Its Web3 stack delivers serious throughput with low costs that keep users and builders active.

Institutional attention continues to grow, including large treasury strategies and fund inflows that strengthen confidence in Solana’s runway.

Even after headline scares around third-party exploits, the network’s momentum and technical progress support the case for steady, long-horizon growth.

Why Sui (SUI) Price Is Struggling

Sui trades near $3.60 after losing steam. Despite a $50 million buyback and a Robinhood listing, price is down 6.7% from around $4.20.

Fresh token unlocks and fewer big upgrades weigh on sentiment. With RSI at 48.93, signals sit neutral, leaving investors waiting for a catalyst to flip the trend.

The Rise Of Pepeto: A Meme Coin With Real Utility And 100x Potential

Pepeto is climbing the meme ladder fast, blending viral energy with a solid Ethereum, EVM-compatible base.

The presale price is $0.000000157, and funding has reached $6,917,905.48 as buyers rotate from Pepe, Shiba, Dogecoin, and top alts. Staking pays 223% APY, letting early holders compound before listings begin.

A PepetoSwap demo is already live on socials. This zero-fee venue targets fast, gas-free swaps and plans to list the 2026 meme class. With the same 420 trillion supply as Pepe, Pepeto adds the missing rails that power real usage.

And the story sticks. Pepe stood for Power, Energy, Precision, Efficiency. Pepeto owns Technology and Opportunity, turning meme culture into capability.

Fresh Numbers Snapshot: SOL And Pepeto Right Now

Solana trades around $230.59 with a $125.73B market cap, $9.11B in 24h volume, and about 545.23M SOL circulating. Pepeto’s presale sits at $0.000000157 with $6,917,905.48 raised and staking at 223% APY.

Final Thought: Do Not Miss Pepeto Before It Lifts

Sui looks mixed, Solana remains a blue-chip compounder, and Pepeto is the near-term meme leader that marries utility with momentum.

Analysts see room for 50x to 100x if adoption accelerates. Early SHIB, PEPE, and DOGE buyers won by acting before listings. Pepeto is at that same stage today, and the early window will not stay open.

How To Join Pepeto Before It’s Too Late

Connect your MetaMask or Trust Wallet

Go to the official site: pepeto.io

Choose payment with USDT, ETH, BNB, or credit card

Buy at the current presale price of $0.000000157

Stake for 223% APY and hold as the project grows

Website: https://pepeto.io

Telegram: https://t.me/pepeto_channel

X: https://x.com/Pepetocoin


This publication is sponsored. Coindoo does not endorse or assume responsibility for the content, accuracy, quality, advertising, products, or any other materials on this page. Readers are encouraged to conduct their own research before engaging in any cryptocurrency-related actions. Coindoo will not be liable, directly or indirectly, for any damages or losses resulting from the use of or reliance on any content, goods, or services mentioned. Always do your own research.

The post Solana And Pepeto Should Be On Your Radar Today,As SUI Struggles appeared first on Coindoo.

Market Opportunity
SUI Logo
SUI Price(SUI)
$0.9455
$0.9455$0.9455
-1.21%
USD
SUI (SUI) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26